Abstract
The aetiological agent of tuberculosis (TB), Mycobacterium tuberculosis, is responsible for millions of deaths annually. The increasing prevalence of the disease, the emergence of multidrug-resistant strains, and the devastating effect of human immunodeficiency virus co-infection have led to an urgent need for the development of new and more efficient antimycobacterial drugs. Since the shikimate pathway is present and essential in algae, higher plants, bacteria, and fungi, but absent from mammals, the gene products of the common pathway might represent attractive targets for the development of new antimycobacterial agents. In this review we describe studies on shikimate pathway enzymes, including enzyme kinetics and structural data. We have focused on mycobacterial shikimate pathway enzymes as potential targets for the development of new anti-TB agents.
Keywords: 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase, 3-dehydroquinate synthase, 3-dehydroquinate dehydratase, shikimate 5-dehydrogenase, shikimate kinase, 5-enolpyruvylshikimate-3-phosphate synthase, chorismate synthase, antimycobacterial drug design
Current Drug Targets
Title: Mycobacterial Shikimate Pathway Enzymes as Targets for Drug Design
Volume: 8 Issue: 3
Author(s): R. G. Ducati, L. A. Basso and D. S. Santos
Affiliation:
Keywords: 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase, 3-dehydroquinate synthase, 3-dehydroquinate dehydratase, shikimate 5-dehydrogenase, shikimate kinase, 5-enolpyruvylshikimate-3-phosphate synthase, chorismate synthase, antimycobacterial drug design
Abstract: The aetiological agent of tuberculosis (TB), Mycobacterium tuberculosis, is responsible for millions of deaths annually. The increasing prevalence of the disease, the emergence of multidrug-resistant strains, and the devastating effect of human immunodeficiency virus co-infection have led to an urgent need for the development of new and more efficient antimycobacterial drugs. Since the shikimate pathway is present and essential in algae, higher plants, bacteria, and fungi, but absent from mammals, the gene products of the common pathway might represent attractive targets for the development of new antimycobacterial agents. In this review we describe studies on shikimate pathway enzymes, including enzyme kinetics and structural data. We have focused on mycobacterial shikimate pathway enzymes as potential targets for the development of new anti-TB agents.
Export Options
About this article
Cite this article as:
Ducati G. R., Basso A. L. and Santos S. D., Mycobacterial Shikimate Pathway Enzymes as Targets for Drug Design, Current Drug Targets 2007; 8 (3) . https://dx.doi.org/10.2174/138945007780059004
DOI https://dx.doi.org/10.2174/138945007780059004 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Insights into Lipidic Secondary Metabolites in Mycobacteria
Current Chemical Biology Molecular Modeling Based Synthesis and Evaluation of <i>In vitro</i> Anticancer Activity of Indolyl Chalcones
Current Topics in Medicinal Chemistry Drug Delivery Systems: A Few Examples of Applications, Drug Cargoes, and Administration Routes
Current Pharmaceutical Design Decaprenylphosphoryl-β-D-Ribose 2-Epimerase from Mycobacterium tuberculosis is a Magic Drug Target
Current Medicinal Chemistry Current Discovery Progress of Some Emerging Anti-infective Chalcones: Highlights from 2016 to 2017
Current Drug Discovery Technologies Natural T Cell Immunity to Intracellular Pathogens and Nonpeptidic Immunoregulatory Drugs
Current Molecular Medicine ITK Inhibitors in Inflammation and Immune-Mediated Disorders
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Progress in Neglected Disease Drug Discovery (Guest Editors: Andrew L. Hopkins & Paul G. Wyatt)]
Current Topics in Medicinal Chemistry Progress in Nanoparticulate Systems for Peptide, Proteins and Nucleic Acid Drug Delivery
Current Pharmaceutical Biotechnology Matrix Metalloproteinases in Respiratory Diseases: From Pathogenesis to Potential Clinical Implications
Current Medicinal Chemistry Understanding Membrane Protein Drug Targets in Computational Perspective
Current Drug Targets Three-Dimensional Quantitative Structure-Activity Relationships for a Large Series of Potent Antitubercular Agents
Letters in Drug Design & Discovery Applications and Case Studies of the Next-Generation Sequencing Technologies in Food, Nutrition and Agriculture
Recent Patents on Food, Nutrition & Agriculture PET Imaging for Gene & Cell Therapy
Current Gene Therapy Polyene Macrolide Antibiotic Biosynthesis
Current Medicinal Chemistry Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19
Current Medicinal Chemistry Molecular Properties Prediction and Synthesis of Novel Pyrazoline Carboxamide Analogs as Antitubercular Agents
Anti-Infective Agents Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Antimicrobial Peptide Precursor Structures Suggest Effective Production Strategies
Recent Patents on Inflammation & Allergy Drug Discovery Retinoic Acid and Iron Metabolism: A Step Towards Design of a Novel Antitubercular Drug
Current Pharmaceutical Biotechnology